MA44781A - Composé hétérocyclique condensé - Google Patents

Composé hétérocyclique condensé

Info

Publication number
MA44781A
MA44781A MA044781A MA44781A MA44781A MA 44781 A MA44781 A MA 44781A MA 044781 A MA044781 A MA 044781A MA 44781 A MA44781 A MA 44781A MA 44781 A MA44781 A MA 44781A
Authority
MA
Morocco
Prior art keywords
heterocyclic compound
condensed heterocyclic
condensed
compound
heterocyclic
Prior art date
Application number
MA044781A
Other languages
English (en)
Other versions
MA44781B1 (fr
Inventor
Hiroshi Banno
Keisuke Imamura
Shinichi Imamura
Yoshiteru Ito
Youichi Kawakita
Takuto Kojima
Xin Liu
Noriyuki Nii
Koji Ono
Nobuki Sakauchi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA44781A publication Critical patent/MA44781A/fr
Publication of MA44781B1 publication Critical patent/MA44781B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA44781A 2016-04-28 2017-04-27 Composé hétérocyclique condensé MA44781B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016091717 2016-04-28
PCT/JP2017/016717 WO2017188374A1 (fr) 2016-04-28 2017-04-27 Composé hétérocyclique condensé

Publications (2)

Publication Number Publication Date
MA44781A true MA44781A (fr) 2019-03-06
MA44781B1 MA44781B1 (fr) 2022-10-31

Family

ID=60159711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44781A MA44781B1 (fr) 2016-04-28 2017-04-27 Composé hétérocyclique condensé

Country Status (20)

Country Link
US (3) US10577382B2 (fr)
EP (1) EP3450436B1 (fr)
JP (2) JP6924182B2 (fr)
KR (1) KR102431405B1 (fr)
CN (1) CN109415384B (fr)
BR (1) BR112018072039B1 (fr)
CA (1) CA3021185C (fr)
DK (1) DK3450436T3 (fr)
EA (1) EA039529B1 (fr)
ES (1) ES2927529T3 (fr)
HR (1) HRP20221277T1 (fr)
HU (1) HUE059954T2 (fr)
LT (1) LT3450436T (fr)
MA (1) MA44781B1 (fr)
PL (1) PL3450436T3 (fr)
PT (1) PT3450436T (fr)
RS (1) RS63656B1 (fr)
SG (2) SG11201809243YA (fr)
SM (1) SMT202200424T1 (fr)
WO (1) WO2017188374A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039529B1 (ru) * 2016-04-28 2022-02-07 Такеда Фармасьютикал Компани Лимитед Конденсированные гетероциклические соединения
CN113773247A (zh) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 一种2-氨基-5-碘吡啶的制备方法
CN119053329A (zh) 2022-03-31 2024-11-29 日商科迪亚制药股份有限公司 利用咪唑并[4,5-b]吡啶衍生物治疗实体瘤的生物标志物
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法
WO2025078334A1 (fr) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combinaison d'inhibiteurs de pak1 et d'inhibiteurs de clk pour prévenir la résistance à la chimiothérapie chez des patients souffrant de leucémie myéloïde aiguë
WO2025150571A1 (fr) * 2024-01-12 2025-07-17 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 Agent de traitement du cancer contenant un inhibiteur de clk en tant que principe actif
WO2025256640A1 (fr) * 2024-06-14 2025-12-18 北京康辰药业股份有限公司 Composé macrocyclique, composition pharmaceutique à base de celui-ci et utilisation associée

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ES2258459T3 (es) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
BRPI0917540A2 (pt) * 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
JP2013501792A (ja) * 2009-08-10 2013-01-17 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔ／ｂ−カテニンシグナル伝達経路阻害剤としてのインダゾールおよびその治療的使用
PL2464232T3 (pl) * 2009-08-10 2016-04-29 Samumed Llc Indazolowe inhibitory szlaku sygnałowego Wnt i ich zastosowania terapeutyczne
WO2012003576A1 (fr) * 2010-07-06 2012-01-12 Université de Montréal Dérivés d'imidazopyridine, d'imidazopyrimidine et d'imidazopyrazine en tant que modulateurs des récepteurs de mélanocortine-4
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
EA039529B1 (ru) * 2016-04-28 2022-02-07 Такеда Фармасьютикал Компани Лимитед Конденсированные гетероциклические соединения

Also Published As

Publication number Publication date
CN109415384B (zh) 2022-01-11
SG10201912270PA (en) 2020-02-27
JPWO2017188374A1 (ja) 2019-02-28
US20210115067A1 (en) 2021-04-22
WO2017188374A1 (fr) 2017-11-02
DK3450436T3 (da) 2022-09-12
HRP20221277T1 (hr) 2022-12-23
RS63656B1 (sr) 2022-11-30
US10981934B2 (en) 2021-04-20
EP3450436A1 (fr) 2019-03-06
MA44781B1 (fr) 2022-10-31
US10577382B2 (en) 2020-03-03
KR102431405B1 (ko) 2022-08-10
EP3450436B1 (fr) 2022-07-27
CA3021185C (fr) 2024-06-04
LT3450436T (lt) 2022-09-12
SMT202200424T1 (it) 2022-11-18
CN109415384A (zh) 2019-03-01
JP6924182B2 (ja) 2021-08-25
JP2021176901A (ja) 2021-11-11
CA3021185A1 (fr) 2017-11-02
US20200140462A1 (en) 2020-05-07
EA039529B1 (ru) 2022-02-07
KR20190002547A (ko) 2019-01-08
PT3450436T (pt) 2022-09-29
JP7130098B2 (ja) 2022-09-02
PL3450436T3 (pl) 2022-12-27
HUE059954T2 (hu) 2023-01-28
EP3450436A4 (fr) 2019-10-30
EA201892449A1 (ru) 2019-05-31
ES2927529T3 (es) 2022-11-08
US20190106437A1 (en) 2019-04-11
US11390634B2 (en) 2022-07-19
BR112018072039B1 (pt) 2023-12-26
SG11201809243YA (en) 2018-11-29
BR112018072039A2 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
EP3438109A4 (fr) Composé hétérocyclique
MA45940A (fr) Composé hétérocyclique
EP3366684A4 (fr) Composé hétérocyclique
DK3436444T3 (da) Heterocyklisk forbindelse
EP3689879A4 (fr) Composé hétérocyclique
EP3360864A4 (fr) Composé pyrimidine
EP3327019A4 (fr) Composé hétérocyclique
EP3438140A4 (fr) Composé thermodurcissable
EP3372604A4 (fr) Composé hétérocyclique condensé
EP3366679A4 (fr) Composé hétérocyclique
EP3444239A4 (fr) Composé hétérocyclique
EP2955179A4 (fr) Composé hétérocyclique condensé
EP3354638A4 (fr) Composé de phtalonitrile
EP3450436A4 (fr) Composé hétérocyclique condensé
EP2955178A4 (fr) Composé hétérocyclique condensé
EP3424905A4 (fr) Composé hétérocyclique
EP3467106A4 (fr) Composé peptidique
EP3299355A4 (fr) Composé de phtalonitrile
EP3533799A4 (fr) Composé
EP3578549A4 (fr) Composé hétérocyclique
EP3438103A4 (fr) Composé de griséofulvine
EP3372588A4 (fr) Composé de pyrimidine
EP3782986A4 (fr) Composé hétérocyclique
EP3660003A4 (fr) Composé hétérocyclique
MA43275A (fr) Composé de pyranodipyridine